Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P51649
UPID:
SSDH_HUMAN
Alternative names:
Aldehyde dehydrogenase family 5 member A1; NAD(+)-dependent succinic semialdehyde dehydrogenase
Alternative UPACC:
P51649; B2RD26; G5E949; Q546H9; Q8N3W6
Background:
Succinate-semialdehyde dehydrogenase, mitochondrial, also known as Aldehyde dehydrogenase family 5 member A1, plays a crucial role in the degradation of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). This enzyme's activity is pivotal in maintaining the balance of GABA in the nervous system.
Therapeutic significance:
Succinic semialdehyde dehydrogenase deficiency, a rare metabolic disorder, is directly linked to mutations in this enzyme, leading to severe neurological symptoms. Understanding the enzyme's function could pave the way for innovative treatments for this debilitating condition.